HTG Molecular Diagnostics And QIAGEN Team Up To Advance Precision Diagnostics

TUCSON, Ariz., and VENLO, the Netherlands, Nov. 16, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ("HTG"), a provider of instruments and reagents for molecular profiling applications and QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NASDAQ:QGEN) (Frankfurt Stock Exchange:QIA); "QIAGEN"), announced a Master Assay Development, Commercialization and Manufacturing Agreement ("Agreement").  This Agreement creates a framework for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies a complete NGS-based solution for the development and commercialization of companion diagnostics, with a focus in oncology.  Together with the parties' entry into the Agreement, QIAGEN North American Holdings, Inc., another QIAGEN subsidiary, made a minority investment in HTG's common stock.

"We are very impressed with QIAGEN's Sample to Insight philosophy and quickly envisioned development and commercial synergies through our combined efforts with pharma," said TJ Johnson, HTG's President and Chief Executive Officer.  "Our objective is to develop a complete NGS solution from biomarker discovery to commercialized companion diagnostics and we believe this agreement accelerates both companies' efforts. We are excited to offer this solution to customers," added Mr. Johnson.

"HTG's extraction free technology can add attractive capabilities to QIAGEN's NGS-based Sample to Insight solutions for applications in pathology where sample often is limited," said Kai te Kaat, Vice President, Head of Franchise Oncology, Molecular Diagnostics Business Area at QIAGEN. "The addition of HTG's technology to our Sample to Insight GeneReader NGS system, and augmented by QIAGEN's capabilities across NGS workflows, will enable our pharma partners to successfully profile patients including settings where only low sample amounts are available. This capability is of interest in many indication areas but primarily in oncology and immune-oncology applications."

About HTG:

Headquartered in Tucson, Arizona, HTG's mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG's product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.

HTG Safe Harbor Statement: 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the anticipated benefits of our agreement with QIAGEN Manchester Limited, and our ability to successfully develop next-generation sequencing (NSG)-based solutions for biomarker discovery through commercialized companion diagnostics, and support the development, regulatory filing and commercialization of companion diagnostics. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that we may not realize the expected benefits from our agreement with QIAGEN Manchester Limited, risks associated with the utility of our automation systems, proprietary profiling panels and solutions, and our ability to successfully manufacture and supply our products. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including, without limitation, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

If you liked this article you might like

The Bears Continue to Be Frustrated

Health Care Vote Impacts Trump's Deal Maker Image